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Abstract
Purpose: Randomized, multicenter, open-label, phase 2/3 trial
investigating lenalidomide versus investigator's choice (IC) in
relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Experimental Design: Patients with DLBCL who received 2
prior therapies were stratified by DLBCL subtype [germinal center
B-cell (GCB) vs. non-GCB; determined by immunohistochemis-
try (IHC)] and then randomized 1:1 to lenalidomide (25mg/day,
21 days of 28-day cycle) or IC (gemcitabine, rituximab, etoposide,
or oxaliplatin). Crossover to lenalidomide was permitted for IC-
treatedpatientswith radiologically confirmedprogressive disease.
The primary endpoint was overall response rate (ORR). Progres-
sion-free survival (PFS), overall survival, and subtype analysis
[GCB vs. activated B-cell (ABC)] using gene expression profiling
(GEP) were exploratory endpoints.
Results: Stage 1: 102 DLBCL patients (by IHC: non-GCB, n ¼
54; GCB, n ¼ 48) received 1 dose of lenalidomide or IC.
Hematologic treatment-emergent adverse events with lenalido-
mide versus IC included neutropenia (42.6%; 36.4%), anemia
(33.3%; 47.3%), thrombocytopenia (24.1%; 43.6%), and leu-
kopenia (5.6%; 12.7%), respectively. Overall, lenalidomide-
treated patients had an ORR of 27.5% versus 11.8% in IC
(ORRs were similar regardless of IHC-defined DLBCL subtype).
Median PFS was increased in patients receiving lenalidomide
(13.6 weeks) versus IC (7.9 weeks; P ¼ 0.041), with greater
improvements in non-GCB patients (15.1 vs. 7.1 weeks, respec-
tively; P ¼ 0.021) compared with GCB (10.1 vs. 9.0 weeks,
respectively; P ¼ 0.550).
Conclusions: The clinical benefit of lenalidomide monother-
apy in DLBCL patients was more evident in the non-GCB
subtype. Exploratory analyses suggest that this preferential ben-
efit was more pronounced in the GEP-defined ABC population,
demonstrating a need for additional studies of lenalidomide in
DLBCL using GEP subtyping. Clin Cancer Res; 23(15); 4127–37.
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Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common
subtype of non-Hodgkin lymphoma (NHL) and is aggressive in
nature (1). Overall survival (OS) rates range from 30% to 50%
over 5 years (1), and approximately 60% of patients will remain
disease-free following standard immunochemotherapy (2, 3).
Although front-line R-CHOP (rituximab-cyclophosphamide,
doxorubicin, vincristine, prednisone) can improve clinical out-
comes in DLBCL, 20% to 25% of patients relapse after initial
response to therapy (4, 5). Currently, no agents are approved for
relapsed/refractory DLBCL by the FDA. The European Medicines
Agency has granted conditional approval for the cytotoxic aza-
anthracenedione pixantrone for multiply relapsed/refractory
NHL (6).
DLBCL is a heterogeneous malignancy comprising multiple
subtypes based on cell-of-origin that influence clinical presenta-
tion, prognosis, and treatment response (7, 8). Germinal center B-
cell (GCB) and non-GCB subtypes can be distinguished using
immunohistochemistry (IHC; ref. 9), whereas the more precise,
gold-standard method of gene expression profiling (GEP) is
capable of distinguishing three categories—GCB, activated B-cell
(ABC), and unclassified (8, 10). Patients with ABC subtypes have
an inferior outcome versus GCB patients when treated with
immunochemotherapy. In addition, a subset of DLBCL patients
(20% to 30%; characterized by an aggressive clinical course and
poor response to conventional chemotherapy) express high levels
of MYC and BCL-2 proteins by IHC, and are termed double-
expressors (3, 11).
Lenalidomide (Revlimid) is an IMiD immunomodulatory
agent with activity in multiple NHL subpopulations (12), includ-
ing heavily pretreated, relapsed/refractory DLBCL (13–15). In a
phase 2 trial investigating lenalidomide monotherapy, patients
with DLBCL (N ¼ 108) achieved a 28% overall response rate
(ORR) and 2.7 months' median progression-free survival (PFS;
ref. 14). In a retrospective analysis (N¼ 40), anORRof 27.5%was
observed in lenalidomide-treated patients with DLBCL; patients
with the non-GCB subtype (by IHC) achieved higher ORR
(52.9%) than the GCB subtype (8.7%; P ¼ 0.006; ref. 13).
The antilymphoma activity of lenalidomide is mediated
through multiple mechanisms including inhibiting proliferation
of ABC-subtype DLBCL cells (16), increased T-cell activation and
cytokine production (17), and enhancement of antibody-depen-
dent cellular cytotoxicity (ADCC; ref. 18). Initial observations of
lenalidomide's mechanism of action showed the importance of
decreased expression of interferon regulatory factor 4 (IRF4) and
Spi-B transcription factor (SPIB), as well as inhibition of B-cell
receptor–dependent NFkB activation in ABC-subtype DLBCL cell
lines (19). Subsequent preclinical studies revealed that the cell-
autonomous antilymphoma activity of lenalidomide is derived
from ubiquitination and subsequent proteasomal degradation of
the transcription factors Aiolos and Ikaros by the CRL4CRBN E3
ligase complex. Aiolos functions as a direct transcriptional repres-
sor of interferon-stimulated genes (ISG), and Aiolos degradation
by lenalidomide treatment results in upregulated ISG levels,
independent of interferon beta production (20). Expression of
CRBN/Aiolos and lenalidomide sensitivity in DLBCL is currently
unknown.
Based on prior clinical observations of enhanced benefit in
non-GCB patients, and to define activity of lenalidomide relative
to double-expressor status or CRBN and Aiolos levels, the current
study evaluated the efficacy and safety of lenalidomide versus
investigator's choice (IC) in relapsed/refractory DLBCL patients.
Patients and Methods
Patient eligibility
Eligible patientswere adults (18 years old)with histologically
confirmed DLBCL who had relapsed or were refractory to 1
chemotherapy regimen containing rituximab and an anthracy-
cline/anthracycline equivalent as well as 1 additional combi-
nation chemotherapy regimen, which had to include 1 treat-
ment of ifosfamide, gemcitabine, etoposide, or a platinum agent,
and, if not previously administered, rituximab; or conditioning
regimen containing an alkylating agent followedby autologous or
allogeneic stem cell transplant (SCT). Patients could be exempted
from the additional treatment requirement if they were docu-
mented as being ineligible for both the second combination
chemotherapy and SCT at the time of inclusion in the study.
Other requirements were DLBCL subtype results by IHC from
central pathology; measurable disease (2 cm longest diameter);
Eastern Cooperative Oncology Group performance status 0–2;
life expectancy >3 months; and a formalin-fixed paraffin-embed-
ded (FFPE) tumor block or if possible, fresh frozen tumor sample.
Patients with a diagnosis of NHL other than DLBCL or previous
lenalidomide treatment were excluded.
Study design
DLC-001 was a phase 2/3, randomized, multicenter, open-
label, two-stage trial to determine the efficacy and safety of single-
agent lenalidomide versus IC in relapsed/refractory DLBCL
patients. The objective of stage 1 was to select appropriate DLBCL
subtypes for testing in stage 2. Stage 1 results are presented herein.
The stage 1 primary endpoint ORR was determined by an Inde-
pendent Response Assessment Committee (IRAC) and is defined
by the sum of complete response (CR), CR unconfirmed (CRu),
and partial response (PR) rates as recommended by the Interna-
tional Workshop Response Criteria (IWRC 1999; ref. 21). No
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types,whereas gene expressionprofiling (GEP) candistinguish
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fied. The ABC subtype in particular is poorly responsive to
standard immunochemotherapy, highlighting the need for
additional treatment options. In this study, we report prom-
ising clinical activity with lenalidomide monotherapy in
patients with DLBCL, especially in the GEP-defined ABC
population. These data underscore a need for additional
studies of lenalidomide in DLBCL using GEP subtyping and
provide additional rationale for studies such as the ongoing
phase 3 trial, ROBUST (NCT02285062) comparing lenalido-
mide plus immunochemotherapy versus immunochemother-
apy alone in patients with treatment-na€ve ABC-subtype
DLBCL selected by GEP.
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secondary endpoints were defined for stage 1. Exploratory end-
points for stages 1 and 2 included analyses of CR rate, duration of
overall response, duration of CR/objective response, PFS, OS, and
DLBCL subtype using GEP. The intent-to-treat (ITT) population
was defined as all randomized patients. The safety populationwas
defined as all randomized patients who received1 dose of study
treatment. The primary efficacy analysis was performed on the
modified ITT (mITT) population, defined as all randomized
patients who had confirmed DLBCL and GCB or non-GCB sub-
type diagnosis and received1 dose of study drug. This study was
conducted in accordance with the Declaration of Helsinki and
Good Clinical Practice guidelines. Prior to study commencement,
the protocol, the proposed informed consent form, and other
information for patientswas reviewed and approvedby aproperly
constituted Institutional Review Board/Independent Ethics Com-
mittee at each participating institution. All patients provided
written informed consent.
Before stage 1 randomization, IHC was conducted by central
pathology to confirm DLBCL diagnosis and subtype. Patients
were stratified based on DLBCL subtype (GCB or non-GCB) and
randomized 1:1 to receive lenalidomide or IC (Supplementary
Fig. S1). Lenalidomide dose was based on creatinine clearance
(CrCl)—patients received either 25mg (CrCl60mL/min) or 10
mg (CrCl 30 mL/min but <60 mL/min) once daily for 21 days
(day 1 to day 21) in each 28-day cycle until progressive disease
(PD), unacceptable toxicity, or voluntary withdrawal. Patients
randomized to IC (single-agent gemcitabine, rituximab, etopo-
side, or oxaliplatin) were treated following a suggested standard
regimen (Supplementary Table S1) until treatment completion,
PD, unacceptable toxicity, or voluntary withdrawal. At the time of
radiologically documented relapse or PD, patients receiving IC
had the option to receive crossover lenalidomide.
The independent reviewers interpreted imaging studies and
relevant clinical data for study subjects using an adaptation of the
response criteria for NHLs from the IWRC 1999 for the primary
assessment (21). The IWRC 1999 criteria for assessment were
selected based on investigator consensus and the availability of
standardized imagining modalities at the various study sites.
Adverse events (AE) and serious AE (SAE)were gradedusing the
National Cancer Institute Common Terminology Criteria for
Adverse Events (NCI CTCAE) Version 4.03. Tumor flare reaction
was graded using NCI CTCAE Version 3.0.
Stage 2 of the study was not opened for enrollment because the
stage 1 efficacy results as assessed by the IRAC did not meet the
protocol-specified threshold.
Dose modification/interruption criteria
Dosemodification/interruptionof lenalidomidewas required in
the event of specific toxicities such as grade 2 allergic reaction; grade
2 tumor lysis syndrome; or grade 3 neutropenia (grade 3
sustained7 days or associated with fever or any grade 4), throm-
bocytopenia, or venous thrombosis/embolism. Lenalidomide dis-
continuation was required in the event of desquamating grade 3
or non-desquamating grade 4 rash, or grade 3 allergic reaction.
Dose interruption or modification of IC treatment was permitted
under the clinical practice of the investigator's institution.
Immunohistochemistry
Subtyping on FFPE or fresh-frozen lymph node/tumor tissues
was performedper patient at study entry using theHans algorithm
(9). Central pathology laboratories included the Centre for Lym-
phoid Cancers, British Columbia Cancer Agency (Vancouver,
Canada), and CHU Toulouse Purpan, Laboratoire d'Anatomie
Pathologique. Four-micron-thick FFPE tumor sections were
stained with antibodies to c-myc (clone Y69; Abcam), BCL-2
(clone 124; DAKO), CRBN (rabbit monoclonal antibody; Cel-
gene CRBN65), and Aiolos (rabbit monoclonal antibody; Cel-
gene Clone 9B-9-7), using the Bond-Max automated slide strainer
(LeicaMicrosystems) and the Bond Polymer RefineDetection Kit.
Antigen retrieval was performedwith Epitope Retrieval 2 (pH9.0)
for 20 minutes at 100C on the instrument. The slides were
blocked for endogenous peroxidase activity with Peroxide Block
for 5 minutes at room temperature. Sections were then incubated
with primary antibodies for 15 minutes at room temperature.
Horseradish peroxidase–labeled Polymer was applied at the
instrument's default conditions, and diaminobenzidine tetrahy-
drochloride was used as the enzyme substrate to visualize specific
antibody localization. Slides were counterstained with hematox-
ylin. Markers used to distinguish GCB from non-GCB subtypes
were CD10, BCL6, and MUM1. For distinguishing GCB from
non–GCB-based levels of CD10, BCL6, and MUM-1, a priori
scoring criteria were established before trial enrollment and the
first 50 cases were used for a cross-laboratory IHC validation
analysis. H-scores for CRBN and Aiolos were generated with H-
score ¼ S(1 þ i)pi, where i is the intensity score and pi is the
percentage of the cells with the corresponding intensity.
Molecular characterization
Gene expression profiling subtyping on fresh-frozen lymph/
node/tumor tissues was batch performed at study conclusion.
RNA samples were extracted using the AllPrep DNA/RNA Kit
(Qiagen). Total RNA was amplified and labeled using Sensation-
Plus FFPE Reagent Kit and then hybridized on Affymetrix U133
Plus 2.0 GeneChips (Affymetrix) following vendor instructions.
Samples were classified as ABC, GCB, or unclassified DLBCL in a
blinded fashion using a Bayesian model based on a linear pre-
dictor score formed from the expression of genes that distinguish
these two subtypes as previously described (7, 22).
DNA sequencing of mutations in
lymphoma-associated genes
Genomic DNA from patient samples was extracted with the
AllPrep DNA/RNA Kit (Qiagen) according to the manufacturer's
instructions. PCR was performed with a GeneAmp XL PCR
kit (Applied Biosystems) as previously described (23, 24). The
sequences for primers applied to amplify MYD88, CD79A,
CD79B, CARD11, and TNFAIP3 are summarized in Supplemen-
tary Table S2. The PCR products were visualized by electropho-
resis on a 1% agarose gel and ethidium bromide staining. The
templates were purified using the QuickStep2 96-well PCR puri-
fication Kit (Edge BioSystems) and subsequently sequenced (Big-
Dye sequencing system, Applied Biosystems). Mutations were
confirmed on independent PCR products and sequenced from
both strands.
Genetic mutations in the B-cell receptor (BCR) pathway have
been shown to result in constitutive activity of NFkB, leading to
deregulated proliferation and survival signals (23, 25). In addi-
tion, mutations in this pathway are predicted to result in intrinsic
resistance to targeted agents such as ibrutinib. Indeed, mutations
in CARD11 or TNFAIP3 have been shown to inhibit clinical
response to ibrutinib in R/RDLBCL (26).We therefore performed
targeted sequencing of genes in the BCR pathway (MYD88,
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CD79A, CD79B, CARD11, and TNFAIP3) to understand if muta-
tions abrogated lenalidomide activity.
Statistical analysis
All statistical analyseswere conductedusingSASVersion9.1.3or
higher. Efficacy evaluations were conducted using the mITT and
ITT populations for the primary and supportive analyses, respec-
tively. Statistical comparisons were made between lenalidomide
and IC groups according to initial randomized treatment. The
Kaplan–Meier method was used to estimate survival distribution
functions for each treatment group; median of the survival distri-
bution along with associated two-sided 95% confidence intervals
(CI)was estimated. ACox proportionalhazardsmodelwas used to
estimate the HR along with 95% CIs. In stage 1, a sample size of
25 patients per subtype per treatment group provided 90% power
to detect a 35%difference inORRbetween lenalidomide and IC at
2-sided a¼ 0.15 level assuming a 15%ORR in the IC group and 1
interimanalysis plannedat 60%information level. For theprimary
endpoint, P values were presented for comparison of the best
response rates between treatment groups. The O'Brien–Fleming
approach was used to control the overall type-I error of 15%.
Results
Patient demographics
The ITT population consisted of 111 patients randomized to
lenalidomide (n¼ 54) or IC (n¼ 57). Of these, DLBCL subtyping
was not feasible for 9 patients because of technical difficulties,
resulting in a mITT population of 102 patients with DLBCL
diagnosis and subtype confirmation of non-GCB (n ¼ 54) or
GCB (n¼ 48) by IHC and who received1 dose of lenalidomide
(n ¼ 51) versus IC (n ¼ 51). The IHC analysis for DLBCL
subtyping was conducted by three independent laboratory facil-
ities; the agreement rate among the laboratories was 87.5% to
97.9%. Overall, baseline characteristics in the mITT population
were similar between treatment groups (Table 1). The majority of
patients received2previous systemic chemotherapies (90.2% in
the lenalidomide group vs. 92.2% in IC; P ¼ 0.7270), and nearly
half had received 3 prior systemic chemotherapies (49.0% vs.
62.7%, respectively; P ¼ 0.1627).
Efficacy
IRAC review demonstrated that in the core treatment phase, 14
patients (27.5%) had a clinical response to lenalidomide versus 6
(11.8%) treated with IC (P ¼ 0.079; Table 2). Following lenali-
domide treatment,ORRwashigher inbothDLBCL subtypes versus
IC. Basedon subtypingby IHC(Table2), non-GCBpatients treated
with lenalidomide had anORR of 28.6% [n¼ 8; CR¼ 14.3% (n¼
4)] versus 11.5% [n ¼ 3; CR ¼ 3.8% (n ¼ 1)] for IC; a similar
patternwas observed inGCBpatients, withORRs of 26.1% [n¼ 6;
CR ¼ 4.3% (n ¼ 1)] and 12.0% (n ¼ 3; no CRs), respectively.
Median duration of response based on IRAC review was longer
in the lenalidomide-treated patients (73.9 weeks; 95% CI, 16.4
Table 1. Demographic characteristics in the overall population and DLBCL subtypes as determined by IHC
Overall GCB Non-GCB
Len IC Len IC Len IC
n ¼ 51 n ¼ 51 n ¼ 23 n ¼ 25 n ¼ 28 n ¼ 26
Median age, years (min, max) 69.0
(28.0, 84.0)
65.0
(20.0, 84.0)
70.0
(37.0, 84.0)
64.0
(28.0, 84.0)
67.5
(28.0, 78.0)
66.5
(20.0, 80.0)
Age, n (%)
<65 years 16 (31.4) 25 (49.0) 8 (34.8) 13 (52.0) 8 (28.6) 12 (46.2)
65 years 35 (68.6) 26 (51.0) 15 (65.2) 12 (48.0) 20 (71.4) 14 (53.8)
Sex, n (%)
Male 30 (58.8) 31 (60.8) 13 (56.5) 16 (64.0) 17 (60.7) 15 (57.7)
Female 21 (41.2) 20 (39.2) 10 (43.5) 9 (36.0) 11 (39.3) 11 (42.3)
ECOG PS, n (%)a
0 18 (35.3) 15 (29.4) 6 (26.1) 9 (36.0) 12 (42.9) 6 (23.1)
1 24 (47.1) 28 (54.9) 12 (52.2) 12 (48.0) 12 (42.9) 16 (61.5)
2 7 (13.7) 8 (15.7) 4 (17.4) 4 (16.0) 3 (10.7) 4 (15.4)
Systemic anticancer therapy, n (%)
1b 5 (9.8) 4 (7.8) 2 (8.7) 0 (0.0) 3 (10.7) 4 (15.4)
2 21 (41.2) 15 (29.4) 7 (30.4) 10 (40.0) 14 (50.0) 5 (19.2)
3 25 (49.0) 32 (62.7) 14 (60.9) 15 (60.0) 11 (39.3) 17 (65.4)
ASCT 13 (25) 17 (33.3) 6 (26.1) 8 (32.0) 7 (25.0) 9 (34.6)
Prior anticancer therapies, n (%)c,d
Patients with 1 therapy 51 (100) 51 (100) 23 (100) 25 (100) 28 (100) 26 (100)
R-CHOP 38 (74.5) 35 (68.6) 15 (65.2) 12 (48.0) 23 (82.1) 23 (88.5)
R-ICE 9 (17.6) 15 (29.4) 3 (13.0) 6 (24.0) 6 (21.4) 9 (34.6)
R-DHAP 8 (15.7) 9 (17.6) 4 (17.4) 6 (24.0) 4 (14.3) 3 (11.5)
R-GemOx 5 (9.8) 4 (7.8) 3 (13.0) 3 (12.0) 2 (7.1) 1 (3.8)
Other 5 (9.8) 4 (7.8) 4 (17.4) 3 (12.0) 1 (3.6) 1 (3.8)
aOne patient (GCB subtype) missing from lenalidomide arm and 1 patient (non-GCB subtype) in the lenalidomide arm entered with ECOG PS2 at screening but had 4
at C1D1.
bThese patients were exempt from the requirement for second combination chemotherapy or stem cell transplant on the basis of advanced age alone (n ¼ 1) or in
combination with poor performance status (n ¼ 1), major organ dysfunction or significant medical condition that placed the patient at unacceptable risk at time of
study enrollment (n ¼ 4), or patient decision to decline second-line combination chemotherapy (n ¼ 3).
cA patient with the same regimenmultiple timeswas counted only once. All regimens are listed in descending order of frequency based on the overall ITT population.
dPrior systemic anticancer therapy for DLBCL received by 10% of patients in the overall treatment phase (mITT population).
Abbreviations: ASCT, autologous stem cell transplant; ECOG, Eastern Cooperative Oncology Group; PS, performance status; R-CHOP, rituximab, cyclophosphamide,
doxorubicin, vincristine, prednisone; R-DHAP, rituximab, dexamethasone, high-dose cytarabine, cisplatin; R-GemOx, rituximab, gemcitabine, oxaliplatin; R-ICE,
rituximab, ifosfamide, carboplatin, etoposide.
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weeks–not yet reached) than in IC-treated patients (29.2 weeks;
95% CI, 7.0–43.9 weeks; P ¼ 0.138). Median PFS was 13.6
weeks in patients treated with lenalidomide and 7.9 weeks in
those treated with IC (HR, 0.64; P ¼ 0.041; Fig. 1; Table 2). An
increase in median PFS was observed in non-GCB patients
treated with lenalidomide (15.1 weeks) versus IC (7.1 weeks;
HR, 0.50; P ¼ 0.021), compared with median PFS of 10.1 and
9.0 weeks, respectively, in GCB patients (HR, 0.82; P ¼
0.550; Fig. 1; Table 2).
Patients treated with lenalidomide versus IC achieved similar
OS, irrespective of IHC-definedDLBCL subtype (Table 2);median
OS was 31.0 and 24.6 weeks in lenalidomide and IC arms,
respectively (HR, 0.91; P ¼ 0.673). In non-GCB patients, median
OS with lenalidomide was 32.3 weeks versus 20.4 with IC (HR,
0.70; P ¼ 0.253), compared with 30.0 versus 24.9 weeks (HR,
1.23; P ¼ 0.526) in GCB patients (Fig. 2; Table 2).
Safety evaluation
The safety population consisted of 109 patients. Median
treatment duration was 7.4 weeks in lenalidomide-treated
patients [n ¼ 54; 7.1 weeks non-GCB (n ¼ 28); 9.1 weeks GCB
(n ¼ 24)] versus 5.1 weeks in the IC group [n ¼ 55; 4.1 weeks
non-GCB (n ¼ 28); 5.1 weeks GCB (n ¼ 25)]. Overall, similar
proportions of patients treated with lenalidomide [31 (57.4%)]
versus IC [30 (54.5%)] required 1 dose interruption for AEs.
All patients, irrespective of study treatment or DLBCL subtype,
had 1 treatment-emergent adverse event (TEAE). Grade 3
TEAEs (Supplementary Table S3) were reported in 43 patients
in both lenalidomide (79.6%) and IC (78.2%) groups. Inci-
dence of SAEs was similar across groups: 30 patients (55.6%)
treated with lenalidomide and 30 (54.5%) with IC. Among
common TEAEs reported in 10% of patients (Table 3), nau-
sea, anemia, thrombocytopenia, leukopenia, back pain, hypo-
kalemia, and hyperglycemia were observed more frequently
(difference of 5%) in patients treated with IC, whereas
fatigue, constipation, diarrhea, dry mouth, neutropenia, cough,
bronchitis, rash, and tumor flare reaction were more frequent in
the lenalidomide group.
Efficacy in the GEP population
In an exploratory analysis, DLBCL subtype was retrospec-
tively analyzed using GEP in a subset of patients (n¼ 92). Of 57
patients with clinical outcome data and GEP classification, 25
(n ¼ 11 ABC; n ¼ 14 GCB) were treated with lenalidomide and
32 (n ¼ 16 ABC; n ¼ 16 GCB) with IC. Sixty-nine patients
whose biopsies were interrogated for subtype by IHC and GEP
revealed a concordance between the 2 methods of 82.6%, with
57 of the 69 being correctly identified. The discordance was
the result of 5 non-GCB IHC samples being GEP subtyped as
GCB and 7 GCB IHC samples being GEP subtyped as unclas-
sified (n ¼ 5) or ABC (n ¼ 2).
Lenalidomide treatment resulted in anORRof 45.5%(n¼5) in
ABCpatients versus 18.8% (n¼ 3)with IC (P¼ 0.206; Table 2). In
GCB patients, ORR was 21.4% (n ¼ 3) for lenalidomide and
12.5% (n ¼ 2) for IC (P ¼ 0.642; Table 2). Median PFS in ABC
patients was 82.0 weeks with lenalidomide (n ¼ 11) versus 6.2
weeks with IC (n¼ 16; HR, 0.44; P¼ 0.105), compared with 13.2
weeks with lenalidomide and 7.1 weeks with IC (HR, 0.77; P ¼
0.506), in the GCB DLBCL patients (Fig. 2; Table 2). In patients
with ABC DLBCL treated with lenalidomide, median OS was
108.4 weeks versus 18.6 weeks in IC (HR, 0.47; P ¼ 0.144).
Median OS in GCB patients treated with lenalidomide versus IC
was 30.0 and 20.1 weeks, respectively (HR, 1.12; P ¼ 0.767).
Efficacy in the crossover population
A total of 29 patients (56.9%) from the IC group crossed over to
lenalidomide after radiologically confirmed PD: 16 (55.2%) from
the non-GCB population and 13 (44.8%) from the GCB popu-
lation. ORR in the crossover patients was modest (n ¼ 1; 3.4%).
None of the 29 crossover patients achieved CR, 1 achieved PR, 5
had stable disease, and the majority (n ¼ 22) had PD. The only
responderwas a patientwithnon-GCB (ABCbyGEP)DLBCLwho
maintained a PR for 11.7 weeks. The median treatment duration
for crossover patients was 6.0 weeks, and, based on investigator's
assessment, median PFS was 8.3 weeks. In crossover patients with
non-GCB and GCB DLBCL subtypes, median PFS durations were
6.1 and 8.6 weeks, respectively. In lenalidomide-crossover
Table 2. Response rate based on IRAC assessment (IWRC 1999)a (mITT Population)
Immunohistochemistry Gene expression profiling
Overall GCB Non-GCB GCB ABC
Len IC Len IC Len IC Len IC Len IC
n ¼ 51 n ¼ 51 n ¼ 23 n ¼ 25 n ¼ 28 n ¼ 26 n ¼ 14 n ¼ 16 n ¼ 11 n ¼ 16
ORR, n (%)
[95% CI]b
14 (27.5)
[15.9–41.7]
6 (11.8)
[4.4–23.9]
6 (26.1)
[10.2–48.4]
3 (12.0)
[2.5–31.2]
8 (28.6)
[13.2–48.7]
3 (11.5)
[2.4–30.2]
3 (21.4)
[4.7–50.8]
2 (12.5)
[1.6–38.3]
5 (45.5)
[16.7–76.6]
3 (18.8)
[4.0–45.6]
P valuec 0.079 0.279 0.179 0.642 0.206
CRd, n (%) 5 (9.8) 1 (2.0) 1 (4.3) 0 (0.0) 4 (14.3) 1 (3.8) 1 (7.1) 0 (0.0) 3 (27.3) 1 (6.3)
PR, n (%) 9 (17.6) 5 (9.8) 5 (21.7) 3 (12.0) 4 (14.3) 2 (7.7) 2 (14.3) 2 (12.5) 2 (18.2) 2 (12.5)
SD, n (%) 13 (25.5) 11 (21.6) 5 (21.7) 7 (28.0) 8 (28.6) 4 (15.4) 4 (28.6) 3 (18.8) 2 (18.2) 3 (18.8)
PD/death, n (%) 24 (47.1) 33 (64.7) 12 (52.2) 14 (56.0) 12 (42.9) 19 (73.1) 7 (50.0) 11 (68.8) 4 (36.4) 10 (62.5)
Unknown, n (%) 0 (0.0) 1 (2.0) 0 (0.0) 1 (4.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0)
PFS, weeks 13.6 7.9 10.1 9.0 15.1 7.1 13.2 7.1 82.0 6.2
HR (95% CI) 0.64 (0.41–0.99) 0.82 (0.43–1.57) 0.50 (0.27–0.92) 0.77 (0.35–1.68) 0.44 (0.15–1.23)
P value 0.041 0.550 0.021 0.506 0.105
OS, weeks 31.0 24.6 30.0 24.9 32.3 20.4 30.0 20.1 108.4 18.6
HR (95% CI) 0.91 (0.59–1.41) 1.23 (0.65–2.34) 0.70 (0.38–1.30) 1.12 (0.52–2.42) 0.47 (0.17–1.33)
P value 0.673 0.526 0.253 0.767 0.144
amITT population; defined as all randomized patients who had confirmed DLBCL and GCB or non-GCB subtype diagnosis and received 1 dose of study drug.
bExact CI based on binomial distribution.
cP value derived from the Fisher exact test.
dNo CR unconfirmed observed.
Abbreviation: Len, lenalidomide.
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Figure 1.
PFS in DLBCL subtype populations after treatment with lenalidomide or IC. Kaplan–Meier estimates of PFS are shown for (A) overall population, (B) GCB DLBCL,
and (C) non-GCB DLBCL analyzed by IHC, as well as (D) GCB DLBCL and (E) ABC DLBCL analyzed by GEP.
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Figure 2.
OS in DLBCL subtype populations after treatment with lenalidomide or IC. Kaplan–Meier estimates of OS are shown for (A) overall population, (B) GCB DLBCL, and
(C) non-GCB DLBCL analyzed by IHC, as well as (D) GCB DLBCL and (E) ABC DLBCL analyzed by GEP.
Lenalidomide Versus Investigator's Choice in DLBCL
www.aacrjournals.org Clin Cancer Res; 23(15) August 1, 2017 4133
on August 13, 2019. © 2017 American Association for Cancer Research. clincancerres.aacrjournals.org Downloaded from 
Published OnlineFirst April 5, 2017; DOI: 10.1158/1078-0432.CCR-16-2818 
patients (n¼ 29),medianOSwas 32.7weeks versus 10.1weeks in
the remaining IC-treated patients (n ¼ 22; P ¼ 0.201).
Correlation of cereblon andAiolos protein expression in tumor
biopsies with response to therapy
In 38 evaluable biopsy samples (19 in each arm), staining
intensities for CRBN (total, nuclear, and cytoplasmic) or Aiolos
(nuclear) did not correlate with response to lenalidomide or IC
therapy (Fig. 3A and B). In addition, there was little correlation
between Aiolos and CRBN protein expression in tumor biop-
sies (Fig. 3C).
Efficacy in patients with concurrent expression of MYC and
BCL-2, and in patients with mutations in the B-cell receptor/
NFkB pathway
Thirty-three patients (39.3%) were double-expressor for MYC
and BCL-2 by IHC. In the lenalidomide-treated arm, ORR was
similar for double-expressors (33.3%; n ¼ 6, 2 PR) and non–
double-expressors (33.3%; n ¼ 12, 1 CR, 3 PR). Median PFS was
17.9 weeks (95% CI, 7.3–27.0) for double-expressors and 16.3
weeks (95% CI, 6.4–25.1) for non–double-expressors.
In patients with an identified mutation in the BCR pathway,
ORR with lenalidomide was 28.6% (n ¼ 7; 1 CR, 1 PR) versus
Table 3. Treatment-emergent AEs reported in 20% of patients in any arm in the overall population (safety population)
Overall GCB Non-GCB
Len IC Len IC Len IC
n ¼ 54 n ¼ 55 n ¼ 24 n ¼ 25 n ¼ 28 n ¼ 28
TEAEa n (%) n (%) n (%) n (%) n (%) n (%)
Patients with 1 AE 54 (100) 55 (100) 24 (100) 25 (100) 28 (100) 28 (100)
General disorders and administration-site conditions 40 (74.1) 34 (61.8) 20 (83.3) 14 (56.0) 18 (64.3) 18 (64.3)
Fatigue 18 (33.3) 15 (27.3) 10 (41.7) 6 (24.0) 7 (25.0) 8 (28.6)
Pyrexia 16 (29.6) 16 (29.1) 7 (29.2) 6 (24.0) 9 (32.1) 9 (32.1)
Gastrointestinal disorders 39 (72.2) 37 (67.3) 20 (83.3) 14 (56.0) 18 (64.3) 21 (75.0)
Constipation 16 (29.6) 12 (21.8) 9 (37.5) 4 (16.0) 7 (25.0) 8 (28.6)
Diarrhea 15 (27.8) 12 (21.8) 8 (33.3) 5 (20.0) 7 (25.0) 6 (21.4)
Nausea 10 (18.5) 20 (36.4) 5 (20.8) 7 (28.0) 4 (14.3) 11 (39.3)
Blood and lymphatic system disorders 34 (63.0) 41 (74.5) 14 (58.3) 18 (72.0) 19 (67.9) 21 (75.0)
Neutropenia 23 (42.6) 20 (36.4) 11 (45.8) 10 (40.0) 11 (39.3) 10 (35.7)
Anemia 18 (33.3) 26 (47.3) 6 (25.0) 13 (52.0) 12 (42.9) 11 (39.3)
Thrombocytopenia 13 (24.1) 24 (43.6) 4 (16.7) 15 (60.0) 9 (32.1) 8 (28.6)
Respiratory, thoracic, and mediastinal disorders 29 (53.7) 22 (40.0) 12 (50.0) 10 (40.0) 16 (57.1) 10 (35.7)
Cough 13 (24.1) 6 (10.9) 5 (20.8) 5 (20.0) 8 (28.6) 0 (0.0)
Musculoskeletal and connective tissue disorders 26 (48.1) 20 (36.4) 12 (50.0) 10 (40.0) 14 (50.0) 10 (35.7)
Infections and infestations 25 (46.3) 32 (58.2) 11 (45.8) 12 (48.0) 14 (50.0) 18 (64.3)
aSafety population, defined as all randomized patients who received 1 dose of study treatment.
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Figure 3.
Expression of Cereblon and Aiolos protein levels in lymph node biopsies and correlation with clinical response. A and B, Correlation between immunohistochemical
H-scores for Cereblon (nuclear, cytoplasmic, or total) and Aiolos protein expression in FFPE lymph node biopsies versus best response (CR ¼ red, PR ¼ blue,
SD¼ gray, PD/Death¼ black).C,H-score for eachmarker is graphically represented in a scatter plot, x-axis Aiolos H-score versus y-axis CRBN (nuclear, cytoplasmic,
or total) H-score. r2 values were generated using linear regression analysis. Abbreviations: R, responder; NR, nonresponder.
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18.75% for IC-treated patients (n ¼ 16; 1 CR, 1 PR). In patients
with nomutations identified, ORRwas 29.6%with lenalidomide
(n ¼ 27; 3 CR, 5 PR) versus 8.6% with IC (n ¼ 23; 2 PR). Median
PFS based on mutational status demonstrated no statistical sig-
nificance between lenalidomide and IC-treated patients (data not
shown).
Discussion
In DLC-001, lenalidomide treatment resulted in higher ORR
and longer PFS compared with IC in patients with heavily pre-
treated DLBCL. When analyzed using IHC, the non-GCB popu-
lation benefited from use of lenalidomide monotherapy and
achieved an ORR of 28.6% versus 11.5% in IC. However, explor-
atory analysis using GEP shows a more pronounced benefit after
lenalidomide treatment compared with IC (ORR 45.5% and
18.8%, respectively) that is associated with longer PFS and OS
in ABC patients and supports further investigation of GEP-guided
treatment in DLBCL patients. Additional exploratory investiga-
tions examining lenalidomide response in MYC/BCL-2 positive
patients revealed similar ORR compared with non–double-
expressor patients (33.3% vs. 33.3%), respectively. Although
lenalidomide activity appeared to be independent of the muta-
tional status of genes involved in theBCR/NFkBpathways, such as
MYD88, CD79A, CD79B, CARD11, and TNFAIP3, the small
sample size necessitates additional studies in larger patient popu-
lations as the context of thesemutations relative to cell-of-origin is
an important contributor to the resulting biology.
The ORR in patients who crossed over to lenalidomide was
modest, which might be expected from heavily pretreated
patients who progressed after additional therapy; nonetheless,
increased OS was observed in lenalidomide-crossover patients
(32.7 weeks) versus non-crossover patients (10.1 weeks).
Although the use of IC as the control arm in this study could
be considered a limitation (especially in the context of the IC
regimens including agents that were used in previous lines of
therapy), and patient numbers were small, these results are
promising and warrant further investigation. Results of this
study are consistent with previous investigations, including a
phase 2 study that investigated lenalidomide monotherapy in
patients with DLBCL and reported an ORR of 28% with a
similar AE profile (14). Another phase 2 trial recently showed
that lenalidomide is also effective in relapsed/refractory DLBCL
when combined with the anti-CD20 antibody obinutuzumab,
with 35.2%ORR, 16.9% CR/Cru rate, and 10.6 months median
OS (95% CI, 6.5–NR; ref. 27).
Non-GCB as defined by IHC remains a heterogeneous NHL
population as classic IHC methods cannot distinguish ABC from
other unclassified non-GCB subtypes. GEP is more accurate than
IHC for predicting patient response to R-CHOP therapy (28). In
this study, obvious differences in lenalidomide treatment
response were observed in non-GCB versus ABC, supporting use
of GEPmethods over IHC inDLBCL subtype analysis. Use of GEP
can be restricted due to limited accessibility to equipment and
cost. However, newer technologies are being developed that
utilize themore readily available FFPE tissue samples andproduce
robust, consistent results with speed and high accuracy (29). The
20-gene Lymph2Cx expression assay utilizes FFPE tissue and has
demonstrated >95% concordance with previously published
methods for DLBCL subtype determination, along with applica-
bility to large patient cohorts (29).
Compared with GCB populations, patients with non-GCB/
ABC DLBCL have decreased response to standard chemotherapy
regimens and poor prognosis (8–10, 30). Clinical trials have
demonstrated preferential activity by subtypes with agents such
as lenalidomide, bortezomib, and ibrutinib, supporting the need
to develop personalized therapies effective in high-risk popula-
tions. In one retrospective analysis of relapsed/refractory DLBCL
patients treated with lenalidomide monotherapy (N ¼ 40), non-
GCB patients had more favorable ORR and OS, and significantly
longer PFS versus GCB (6.2 vs. 1.7 months, respectively; P ¼
0.004; ref. 13). In a second, recently published retrospective
analysis in 123 patients with relapsed/refractory DLBCL at medi-
an follow-up of 4.5 years, lenalidomide treatment was associated
with significantly higher response rates in the non-GCB popula-
tion compared with GCB (CR: 32% vs. 0; PR: 33% vs. 3%,
respectively; P < 0.001 for both). Median PFS was also longer
with lenalidomide in the non-GCB population (37 vs. 30months
forGCB;P<0.001; ref. 31). The proteasome inhibitor bortezomib
in combination with DA-EPOCH (dose-adjusted etoposide, vin-
cristine, doxorubicin, cyclophosphamide, and prednisone)
showed significantly higher ORR (83% vs. 13%; P < 0.001) and
medianOS (10.8 vs. 3.4months;P¼0.003) in relapsed/refractory
ABCversusGCBDLBCL subpopulations (N¼49) (32). In a phase
2 trial (N ¼ 70), ibrutinib, a Bruton's tyrosine kinase inhibitor,
elicitedhigherORRs amongpatientswith relapsed/refractory ABC
DLBCL versus GCB (40% and 5.3%, respectively), and PFS of 2.5
and 1.3 months, respectively (33).
Preclinical studies have demonstrated modulation of
CRL4CRBN E3 ligase activity by lenalidomide, resulting in ubiqui-
tination and subsequent proteasomal degradation of Aiolos and
Ikaros, leading to decreased proliferation of ABC-DLCBL cell lines
and activation of immune cells such as T and natural killer cells
(16–18, 20). However, in this study, investigation of Aiolos and
CRBN levels in tumor biopsies revealed a range of expression for
each protein and,more importantly, a lack of correlation between
expression and response to lenalidomide treatment.
Lenalidomide is further being investigated as front-line therapy
in a phase 3 trial, ROBUST (NCT02285062), which will evaluate
the efficacy and safety of lenalidomide plus R-CHOP (R2-CHOP)
versus placebo plus R-CHOP in treatment-na€ve ABC DLBCL as
determinedbyGEP subtype analysis.DLC-001 results suggest that
DLBCL subtyping by GEPmay facilitate patient selection, and the
ROBUST trial could provide further evidence for this approach. In
addition, the phase 3 REMARC (NCT01122472) trial evaluated
maintenance therapy with lenalidomide versus placebo in
responding elderly patients with DLBCL treated with R-CHOP,
and recently reported improved PFS with 2 years of lenalidomide
maintenance therapy versus placebo (34); further analyses from
this study (including subsets based on cell-of-origin subtyping)
are awaited.
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